Even though Osimertinib emerged as an advanced EGFR-TKI that could be used for treatment of lung cancer patients that had progressed on earlier generation EGFR-TKIs, it has emerged that Osimertinib resistance is also a clinical reality12,13. The gene discussed is EGFR; the disease is lung carcinoma.